Raymond James has initiated coverage on Cogent Biosciences Inc (COGT) with a Strong Buy rating as of September 2, 2025. This marks the firm's first assessment of Cogent's investment potential, reflecting its research into the biotechnology company's business dynamics and growth prospects.
Cogent Biosciences, headquartered in Waltham, Massachusetts, specializes in developing precision therapies for genetically defined diseases. The company, which went public on March 29, 2018, has a current market capitalization of $5.4 billion and employs 205 people. Its clinical program features bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is linked to systemic mastocytosis.
The company is also advancing a portfolio of novel targeted therapies aimed at mutations in FGFR2, ErbB2, and PI3Kα. Upcoming earnings reports are scheduled for May 4, 2026, and August 3, 2026, with analysts estimating an EPS of -$0.54 for both quarters.
Analyst ratings, like this one, provide insights based on research and financial models, but they should be considered alongside other factors such as company fundamentals and industry trends. As of November 1, 2025, the consensus rating for Cogent is Buy, with 6 Strong Buy, 8 Buy, and 5 Hold ratings among 19 analysts.
Such decisions reflect a broader assessment of the company's potential in the competitive biotechnology landscape.